Status:
COMPLETED
3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
Up to 80 years
Phase:
PHASE3
Brief Summary
The study assesses the effect of a further 3 years adjuvant treatment with anastrozole vs. an untreated control group after initial 5 years of adjuvant hormone-therapy.
Eligibility Criteria
Inclusion
- No disease recurrence at time of randomization,
- patients with breast cancer after surgery,
- 5 years (+/- 12 months) of prior endocrine therapy
Exclusion
- Premenopausal patients,
- unknown or negative receptor status,
- Secondary malignant tumor
Key Trial Info
Start Date :
January 1 1996
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
856 Patients enrolled
Trial Details
Trial ID
NCT00300508
Start Date
January 1 1996
Last Update
May 1 2009
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Amstetten, Austria
2
Research Site
Bad Ischl, Austria
3
Research Site
Baden, Austria
4
Research Site
Bregenz, Austria